BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10999488)

  • 1. 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.
    Buckley G; Cooper N; Dyke HJ; Galleway F; Gowers L; Gregory JC; Hannah DR; Haughan AF; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Montana JG; Naylor R; Picken CL; Runcie KA; Sabin V; Tuladhar BR; Warneck JB
    Bioorg Med Chem Lett; 2000 Sep; 10(18):2137-40. PubMed ID: 10999488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
    Buckley GM; Cooper N; Davenport RJ; Dyke HJ; Galleway FP; Gowers L; Haughan AF; Kendall HJ; Lowe C; Montana JG; Oxford J; Peake JC; Picken CL; Richard MD; Sabin V; Sharpe A; Warneck JB
    Bioorg Med Chem Lett; 2002 Feb; 12(3):509-12. PubMed ID: 11814830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors.
    Alexander RP; Warrellow GJ; Eaton MA; Boyd EC; Head JC; Porter JR; Brown JA; Reuberson JT; Hutchinson B; Turner P; Boyce B; Barnes D; Mason B; Cannell A; Taylor RJ; Zomaya A; Millican A; Leonard J; Morphy R; Wales M; Perry M; Allen RA; Gozzard N; Hughes B; Higgs G
    Bioorg Med Chem Lett; 2002 Jun; 12(11):1451-6. PubMed ID: 12031318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aryl sulfonamides as selective PDE4 inhibitors.
    Montana JG; Buckley GM; Cooper N; Dyke HJ; Gowers L; Gregory JP; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Miotla J; Naylor RJ; Runcie KA; Tuladhar B; Warneck JB
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2635-40. PubMed ID: 9873594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma.
    Beasley SC; Cooper N; Gowers L; Gregory JP; Haughan AF; Hellewell PG; Macari D; Miotla J; Montana JG; Morgan T; Naylor R; Runcie KA; Tuladhar B; Warneck JB
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2629-34. PubMed ID: 9873593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDE4 inhibitors: new xanthine analogues.
    Montana JG; Cooper N; Dyke HJ; Gowers L; Gregory JP; Hellewell PG; Miotla J; Morris K; Naylor R; Tuladhar B; Warneck JB
    Bioorg Med Chem Lett; 1998 Oct; 8(20):2925-30. PubMed ID: 9873649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.
    Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Ferlenga P; Pradella L
    Bioorg Med Chem Lett; 2000 Oct; 10(19):2235-8. PubMed ID: 11012037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.
    Ashton MJ; Cook DC; Fenton G; Karlsson JA; Palfreyman MN; Raeburn D; Ratcliffe AJ; Souness JE; Thurairatnam S; Vicker N
    J Med Chem; 1994 May; 37(11):1696-703. PubMed ID: 8201604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 8-Methoxyquinolines as PDE4 inhibitors.
    Billah M; Buckley GM; Cooper N; Dyke HJ; Egan R; Ganguly A; Gowers L; Haughan AF; Kendall HJ; Lowe C; Minnicozzi M; Montana JG; Oxford J; Peake JC; Picken CL; Piwinski JJ; Naylor R; Sabin V; Shih NY; Warneck JB
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1617-9. PubMed ID: 12039575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
    He W; Huang FC; Hanney B; Souness J; Miller B; Liang G; Mason J; Djuric S
    J Med Chem; 1998 Oct; 41(22):4216-23. PubMed ID: 9784096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.
    Hughes B; Howat D; Lisle H; Holbrook M; James T; Gozzard N; Blease K; Hughes P; Kingaby R; Warrellow G; Alexander R; Head J; Boyd E; Eaton M; Perry M; Wales M; Smith B; Owens R; Catterall C; Lumb S; Russell A; Allen R; Merriman M; Bloxham D; Higgs G
    Br J Pharmacol; 1996 Jul; 118(5):1183-91. PubMed ID: 8818342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and profile of SCH351591, a novel PDE4 inhibitor.
    Billah M; Cooper N; Cuss F; Davenport RJ; Dyke HJ; Egan R; Ganguly A; Gowers L; Hannah DR; Haughan AF; Kendall HJ; Lowe C; Minnicozzi M; Montana JG; Naylor R; Oxford J; Peake JC; Piwinski JJ; Runcie KA; Sabin V; Sharpe A; Shih NY; Warneck JB
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1621-3. PubMed ID: 12039576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors.
    Pascal Y; Andrianjara CR; Auclair E; Avenel N; Bertin B; Calvet A; Féru F; Lardon S; Moodley I; Ouagued M; Payne A; Pruniaux MP; Szilagyi C
    Bioorg Med Chem Lett; 2000 Jan; 10(1):35-8. PubMed ID: 10636238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of new orally active phosphodiesterase (PDE4) inhibitors.
    Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
    Chem Pharm Bull (Tokyo); 2004 Sep; 52(9):1098-104. PubMed ID: 15340197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
    Kapui Z; Bence J; Boronkay E; Mikus E; Urbán Szabó K; Baranyi A; Arányi P
    Neurobiology (Bp); 1999; 7(1):71-3. PubMed ID: 10746252
    [No Abstract]   [Full Text] [Related]  

  • 16. Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.
    Kim E; Chun HO; Jung SH; Kim JH; Lee JM; Suh BC; Xiang MX; Rhee CK
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2355-8. PubMed ID: 12824033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.
    Hulme C; Poli GB; Huang FC; Souness JE; Djuric SW
    Bioorg Med Chem Lett; 1998 Jan; 8(2):175-8. PubMed ID: 9871649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
    Buckley GM; Cooper N; Dyke HJ; Galleway FP; Gowers L; Haughan AF; Kendall HJ; Lowe C; Maxey R; Montana JG; Naylor R; Oxford J; Peake JC; Picken CL; Runcie KA; Sabin V; Sharpe A; Warneck JB
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1613-5. PubMed ID: 12039574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.
    Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Fattori R; Ferlenga P; Pradella L
    Bioorg Med Chem Lett; 2002 Jan; 12(1):5-8. PubMed ID: 11738561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo.
    Cooper N; Teixeira MM; Warneck J; Miotla JM; Wills RE; Macari DM; Gristwood RW; Hellewell PG
    Br J Pharmacol; 1999 Apr; 126(8):1863-71. PubMed ID: 10372831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.